新辅助化疗对直肠癌患者肿瘤标记物及免疫功能的影响

目的探讨II、III期直肠癌单纯新辅助化疗对肿瘤标记物及免疫功能的影响。 方法分析我院31例II、III期直肠癌单纯新辅助化疗患者数据，并在化疗前后给予监测肿瘤标记物及免疫功能。 结果本组31例患者前后对比肿瘤标志物CEA(P＝0.049)、CA242(P＝0.048)有显著性差异；而CA199未见显著性差异(P＝0.252)。免疫功能中仅B细胞有显著性差异(P＝0.044)，其余总T细胞、辅助T细胞、细胞毒性T细胞、CD4/CD8、自然杀伤细胞、调节性T细胞均未见显著性差异。 结论新辅助化疗可以显著降低II、III期直肠癌患者肿瘤标志物CEA、CA242；而对细胞免疫功能无影响，仅降低B细胞功能。

The influence of neoadjuvant chemotherapy of patients with colorectal cancer in immune function and tumor markers

ObjectiveTo investigate the effects of neoadjuvant chemotherapy of stage II, III retal cancer on immune function and tumor markers. MethodsTo analyze 31 cases patients with rectal cancer of neoadjuvant chemotherapy, and monitor the tumor markers and immune function before and after chemotherapy. ResultsThe comparison of CEA(P=0.049), CA242(P=0.048)levels between before and after chemotherapy in these 31 patients had significant difference; while CA199 has no significant difference(P=0.252). Only B cells immune function had significant difference(P=0.044), the rest of the total T cells, helper T cells, cytotoxic T cells, natural killer cells, CD4/CD8, or regulatory T cells showed no significant difference. Conclusionneoadjuvant chemotherapy can significantly reduce levels of CEA, CA242 patients in II, III stage rectal cancer; and had no effect on cellular immune function, only decreased B cell function.